Pharming (PHARM) Q2 2026 earnings review
Guidance Cut Exposes RUCONEST Weakness, Despite Joenja's Rise
Pharming's Q2 results underscore a difficult transition period. Total revenue fell 3% YoY to $90.2M, prompting a substantial $30M cut to full-year revenue guidance (now $375-395M). The core issue remains RUCONEST, which saw sales drop 10% YoY due to intense competition from new oral on-demand therapies. While management praised a 24% sequential rebound in RUCONEST, the severe guidance downgrade contradicts the 'stabilization' narrative. The bright spot is Joenja, which delivered an accelerating 40% YoY growth to $17.9M. However, operating profit collapsed to $1.3M from $10.8M a year ago, crushed by a $4.9M manufacturing inventory impairment. Pharming is cutting OpEx by $15M to defend its bottom line as it waits for pipeline catalysts.
🐂 Bull Case
Joenja revenue grew 40% to $17.9M. U.S. patients on paid therapy grew to 132. With a pediatric PDUFA date in October 2026 and international launches underway (Germany, Japan), growth drivers are firmly in place.
Management reduced full-year OpEx guidance by $15M (to $315-320M) while still funding $40M in incremental R&D, showing a commitment to preserving capital during the RUCONEST transition.
🐻 Bear Case
Despite retaining 93% of its active patient base, RUCONEST revenue fell 10% YoY, and the company booked a $4.9M inventory impairment indicating unsellable stock. The $30M guidance cut shows competition is taking a heavier toll than initially projected.
Operating profit plummeted to $1.3M (from $10.8M in 25Q2). Even excluding one-offs, adjusted operating profit of $7.9M is a significant deceleration from the prior year's $12.9M, highlighting lost leverage.
⚖️ Verdict: ⚪
Neutral. Joenja's execution is flawless, but it's not yet large enough to offset RUCONEST's erosion. The massive guidance cut resets expectations, making the Q4 pipeline readouts critical for long-term value creation.
Key Themes
Severe Guidance Downgrade Contradicts Stability Claims
Management spent previous quarters aggressively dismissing the threat of new oral competitors (sebetralstat), insisting RUCONEST served a completely distinct 'high-burden' population. Yet, they just slashed FY26 revenue guidance by $30M. While Q2 RUCONEST new enrollments rebounded to 84 (reversing the Q1 slump), the sheer magnitude of the guidance cut suggests underlying churn or pricing concessions are worse than advertised.
Joenja's Multi-Faceted Commercial Momentum
Joenja's trajectory is accelerating. Q2 sales jumped 40% YoY to $17.9M, driven by 132 U.S. patients on paid therapy. Crucially, geographic expansion is materializing: the EU launch began in Germany on July 1, and Japan is launching in August. The FDA also accepted the resubmitted sNDA for pediatric patients (ages 4-11) with a PDUFA date of October 24, 2026. This opens a known pool of 60 identified U.S. pediatric patients.
Manufacturing Inventory Impairments Erode Margins
Gross profit fell 10% YoY, directly hit by a $4.9M manufacturing-related inventory impairment for RUCONEST. Management indicated this relates to inventory 'not expected to be used for commercial sales'. If the active patient base continues to slowly erode, there is a lingering risk of further working capital write-downs as historical production volumes outpace new market realities.
Transformative Pipeline Readouts Approaching
The company's pivot from a single-asset commercial model hinges on expanding leniolisib (Joenja) into broader primary immunodeficiencies. Two fully enrolled Phase II trials (one for genetically defined PIDs, one for CVID) will read out in Q4 2026. Because the CVID population is up to 40x larger than APDS, positive clinical signals (specifically reductions in lymph node/spleen size and improved blood counts) could radically alter Pharming's valuation.
Macro Tailwind: Favorable FX Masking Operational Weakness
The macro environment provided a slight shield this quarter. A strengthening U.S. dollar against the Euro generated a foreign currency gain of $2.9M (vs a $1.9M loss in 25Q2). Without this favorable exchange rate movement, the company's net profit of $1.6M would have likely dipped into negative territory.
Other KPIs
Reversing into negative territory from a positive $12.0M in 1H 2025. The Q2 operating cash outflow was $9.7M. Management attributed this to negative working capital movements, specifically a strategic inventory build to strengthen supply security, lower revenues, and income tax payments.
Decelerating significantly from $12.9M in Q2 2025. This metric strips out the $4.9M inventory impairment and $1.7M in costs for closing the Évry, France site, but still reveals the loss of operating leverage as total revenues decline and royalty fees (to Novartis for Joenja) scale up.
Guidance
Decelerating. A massive $30M reduction from the prior $405-$425M range. The new midpoint ($385M) implies meager 0% to 5% growth over FY25, officially recognizing the drag RUCONEST's competitive headwinds are having on Joenja's growth.
Stable/Improving. Management lowered the expected spend range by $15M from the prior $330-$335M guide. This implies tight 1% to 3% YoY growth and includes $9M in structural G&A savings, allowing the company to absorb the revenue shortfall without completely torching the bottom line.
Key Questions
RUCONEST Inventory Management
You recorded a $4.9M inventory impairment for RUCONEST this quarter. Given the lowered annual revenue guidance, what is the risk of additional inventory write-downs in H2 2026, and how have you adjusted manufacturing volumes to match the new demand reality?
Joenja Pediatric Conversion
With the October PDUFA date for the pediatric sNDA approaching, you have 60 identified patients in the 4-11 age bracket. What is the expected conversion rate onto paid therapy for these patients in the first 6 months post-approval?
OpEx Reduction Specifics
You lowered OpEx guidance by $15M for the year. How much of this reduction is driven by permanent efficiency gains versus the delaying of commercial investments or pipeline R&D into 2027?